{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:50:42Z","timestamp":1793987442568,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only curative option for patients with advanced chronic myeloid leukemia (CML). However, outcome is dismal and of short follow-up. The objective of the study was to determine long-term outcome and risk factors in patients with a history of CML Blast Crisis (BC; <jats:italic>n<\/jats:italic>\u2009=\u200996) or accelerated phase (<jats:italic>n<\/jats:italic>\u2009=\u200951) transplanted between 1990 and 2018. At transplant, patients had a median age of 39 (range 7\u201376) years and were in \u2265CP2 (<jats:italic>n<\/jats:italic>\u2009=\u200970), in AP (<jats:italic>n<\/jats:italic>\u2009=\u200940) or in BC (<jats:italic>n<\/jats:italic>\u2009=\u200937) with a diagnosis-HSCT interval of median 1.9 (range 0.3\u201324.4) years. Overall survival (OS) amounted 34% (95% CI 22\u201346) and progression-free survival (PFS) 26% (95% CI 16-36) at 15 years. Adverse risk factors for OS and PFS were low CD34<jats:sup>+<\/jats:sup> count in the graft, donor age (&gt;36 years) and BC. Cumulative incidence of Non-Relapse Mortality (NRM) was 28% (95% CI\u00a018\u201338) and of relapse (RI) 43% (95% CI\u00a033\u201353) at 15 years. PB-HSCT and HSCT after 2008 were favorable prognostic factors for NRM, while family donor and patient age &gt;39 years were independently associated with higher RI. HSCT resulted in long-term OS in patients with advanced CML. OS was improved in non-BC patients, with donors \u226436 years and with higher CD34<jats:sup>+<\/jats:sup> dose in the graft.<\/jats:p>","DOI":"10.1038\/s41409-021-01410-x","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T21:04:03Z","timestamp":1627679043000},"page":"2834-2841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-1011","authenticated-orcid":false,"given":"Christian","family":"Niederwieser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9605-485X","authenticated-orcid":false,"given":"Elena","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Zubarovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Zabelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Klyuchnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietlinde","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Christopeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-0114","authenticated-orcid":false,"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris V.","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391\u2013402. [cited 2019 Apr 22]","journal-title":"Cancer"},{"key":"1410_CR2","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"1410_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clml.2015.09.007","volume":"15","author":"F P\u00e9rez-Jacoborez-Jacobo","year":"2015","unstructured":"P\u00e9rez-Jacoborez-Jacobo F, Tuna-Aguilar E, Demichelis-G\u00f3mez R, Crespo-Sol\u00eds E, Valencia-Rocha U, Aguayo \u00c1, et al. Prognostic factors, response to treatment, and survival in patients with chronic myeloid leukemia in blast phase: a single-institution survey. clinical lymphoma, myeloma and leukemia. Clin Lymphoma, Myeloma Leuk. 2015;15:778\u201384.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"1410_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","volume":"29","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann R, Sau\u00dfele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol 2016;29:295\u2013307.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1410_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/0002-9343(87)90754-6","volume":"83","author":"HM Kantarjian","year":"1987","unstructured":"Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A. et al.Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.Am J Med. 1987;83:445\u201354.","journal-title":"Am J Med"},{"key":"1410_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.25628","volume":"94","author":"M Lauseker","year":"2019","unstructured":"Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Str\u00f6mberg U, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019;94:1236\u201343.","journal-title":"Am J Hematol."},{"key":"1410_CR7","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim D-W, Olavarria E, Pinilla-Ibarz J, Apperley JF, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123:2875\u201380.","journal-title":"Cancer"},{"key":"1410_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","volume":"92","author":"A Oyekunle","year":"2013","unstructured":"Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 2013;92:487\u201396.","journal-title":"Ann Hematol"},{"key":"1410_CR9","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2019.06.028","volume":"25","author":"A Radujkovic","year":"2019","unstructured":"Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transpl. 2019;25:2008\u201316.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1410_CR10","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"1410_CR11","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1182\/blood.V99.12.4618","volume":"99","author":"M Alizadeh","year":"2002","unstructured":"Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002;99:4618\u201325.","journal-title":"Blood"},{"key":"1410_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/152581601750289028","volume":"10","author":"B Fehse","year":"2001","unstructured":"Fehse B, Chukhlovin A, K\u00fchlcke K, Marinetz O, Vorwig O, Renges H, et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001;10:419\u201325.","journal-title":"J Hematother Stem Cell Res"},{"key":"1410_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"1410_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/leu.2015.281","volume":"30","author":"A Gratwohl","year":"2016","unstructured":"Gratwohl A, Pfirrmann M, Zander A, Kr\u00f6ger N, Beelen D, Novotny J, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016;30:562\u20139. [cited 2020 Jan 26]","journal-title":"Leukemia"},{"key":"1410_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3324\/haematol.2013.089979","volume":"99","author":"S Servais","year":"2014","unstructured":"Servais S, Porcher R, Xhaard A, Robin M, Masson E, Larghero J, et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related\/unrelated donors. Haematologica. 2014;99:519\u201326. [cited 2020 Jul 11]","journal-title":"Haematologica"},{"key":"1410_CR16","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1182\/blood.V99.8.2726","volume":"99","author":"H Bittencourt","year":"2002","unstructured":"Bittencourt H, Rocha V, Chevret S, Soci\u00e9 G, Esp\u00e9rou H, Devergie A, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726\u201333.","journal-title":"Blood"},{"key":"1410_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bbmt.2004.11.018","volume":"11","author":"S-H Lee","year":"2005","unstructured":"Lee S-H, Lee MH, Lee J-H, Min YH, Lee K-H, Cheong J-W, et al. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transpl. 2005;11:122\u20138. [cited 2020 Jul 11]","journal-title":"Biol Blood Marrow Transpl"},{"key":"1410_CR18","first-page":"48","volume":"83","author":"RM Lemoli","year":"1998","unstructured":"Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, et al. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. Haematologica. 1998;83:48\u201355.","journal-title":"Haematologica"},{"key":"1410_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.bbmt.2010.03.024","volume":"16","author":"A Woolfrey","year":"2010","unstructured":"Woolfrey A, Lee SJ, Gooley TA, Malkki M, Martin PJ, Pagel JM, et al. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transpl. 2010;16:1382\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1410_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbmt.2014.09.006","volume":"21","author":"M Eapen","year":"2015","unstructured":"Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, et al. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transpl. 2015;21:55\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1410_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1056\/NEJM198601233140403","volume":"314","author":"JM Goldman","year":"1986","unstructured":"Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202\u20137.","journal-title":"N Engl J Med"},{"key":"1410_CR22","first-page":"509","volume":"12","author":"A Gratwohl","year":"1993","unstructured":"Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transpl. 1993;12:509\u201316.","journal-title":"Bone Marrow Transpl"},{"key":"1410_CR23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502.","journal-title":"Leukemia"},{"key":"1410_CR24","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;97:145. Accessed 4 Mar 2020.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"1410_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","volume":"20","author":"F van Rhee","year":"1997","unstructured":"van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20:553\u201360.","journal-title":"Bone Marrow Transplant"},{"key":"1410_CR26","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","volume":"119","author":"W Saber","year":"2012","unstructured":"Saber W, Opie S, Rizzo JD, Zhang M-J, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119:3908\u201316. [cited 2020 Jan 25]","journal-title":"Blood"},{"key":"1410_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GvHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296\u2013307.","journal-title":"Blood"},{"key":"1410_CR28","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","volume":"24","author":"I Yakoub-Agha","year":"2006","unstructured":"Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N. French Society of Bone Marrow Transplantation and Cellular Therapy et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10\/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695\u2013702. [cited 2020 Jan 25].","journal-title":"J Clin Oncol"},{"key":"1410_CR29","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","volume":"98","author":"C Kollman","year":"2001","unstructured":"Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043\u201351.","journal-title":"Blood"},{"key":"1410_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/leu.2012.210","volume":"27","author":"N Kr\u00f6ger","year":"2013","unstructured":"Kr\u00f6ger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A. MDS Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation et al.Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings.Leukemia. 2013;27:604\u20139. [cited 2020 Nov 5].","journal-title":"Leukemia"},{"key":"1410_CR31","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/bmt.2010.310","volume":"46","author":"HK Al-Ali","year":"2011","unstructured":"Al-Ali HK, Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W, et al. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2011;46:1296\u2013302.","journal-title":"Bone Marrow Transpl"},{"key":"1410_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbmt.2014.09.021","volume":"21","author":"AR Rezvani","year":"2015","unstructured":"Rezvani AR, Storer BE, Guthrie KA, Schoch HG, Maloney DG, Sandmaier BM, et al. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:105\u201312. [cited 2020 Jul 11]","journal-title":"Biol Blood Marrow Transpl"},{"key":"1410_CR33","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477\u201387.","journal-title":"N Engl J Med"},{"key":"1410_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00277-015-2569-7","volume":"95","author":"C Niederwieser","year":"2016","unstructured":"Niederwieser C, Starke S, Fischer L, Krahl R, Beck J, Gruhn B, et al. Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single\/multiple autologous or matched\/mismatched allogeneic stem cell transplantations. Ann Hematol. 2016;95:473\u201381.","journal-title":"Ann Hematol"},{"key":"1410_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","volume":"4","author":"S Adnan Awad","year":"2020","unstructured":"Adnan Awad S, Kankainen M, Ojala T, Koskenvesa P, Eldfors S, Ghimire B, et al. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv. 2020;4:546\u201359. [cited 2021 Mar 20]","journal-title":"Blood Adv"},{"key":"1410_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087\u201392.","journal-title":"Lancet"},{"key":"1410_CR37","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01410-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T09:09:22Z","timestamp":1635844162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01410-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01410-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}